Texas Biotech regulatory update

TXB received two U.S. patents covering its endothelin A receptor (ETA) antagonist program and its VCAM/ VLA-4 program. U.S. Patent No. 5,514,691 covers N-(4-halo-isoxyazolyl)-sulfonamides and derivatives that modulate the activity of endothelin. TXB is conducting preclinical development on a series of ETA antagonists. ...